Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hfgl2 (Human Fibrinogen-like protein 2) inhibitor in preparation of medicaments for treating liver cancer

A technology for the treatment of liver cancer and inhibitors, which is applied in the field of recombinant human hfgl2 microRNA in the preparation of drugs for the treatment of liver cancer, and can solve the problems of tumor cell transfection, difficulty in removing tumor cells, and low targeting specificity

Active Publication Date: 2011-06-08
TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the gene therapy of liver cancer has not achieved a breakthrough so far, and the main problems that need to be solved are: 1) Finding the ideal target gene for tumor specificity: since the occurrence of tumor involves multiple genes, targeting a certain oncogene or anti-cancer Genetic strategies are difficult to effectively control the malignant growth of tumors, especially for gene therapy of liver cancer, so there are fewer ideal target genes to choose from
2) Selective transfer of exogenous genes to target tissues: Another difficulty in tumor gene therapy is the problem of targeted introduction. Most of the tumor-related target molecules discovered so far have low targeting specificity
3) Eliminate small tumor lesions and control their metastasis: Any transgenic technology cannot transfect all tumor cells in the body, and it is difficult to eliminate tumor cells that have not been transfected in the body by simple gene therapy
Nevertheless, the safety, targeting and effectiveness of adenoviral vectors are still the focus of gene therapy. The current research results at home and abroad show that adenoviral vectors have strong immunogenicity and certain cytotoxicity, such as Excessive doses can cause serious adverse reactions, but if the injection dose and the patient's basic conditions are well controlled, local administration is basically safe. Common clinical adverse reactions include fever, chills, and local reactions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hfgl2 (Human Fibrinogen-like protein 2) inhibitor in preparation of medicaments for treating liver cancer
  • Application of hfgl2 (Human Fibrinogen-like protein 2) inhibitor in preparation of medicaments for treating liver cancer
  • Application of hfgl2 (Human Fibrinogen-like protein 2) inhibitor in preparation of medicaments for treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0054] The present invention will be further described in detail below in conjunction with specific embodiments.

[0055] The pcDNA expression vectors and adenovirus expression vectors used in the following experimental methods were purchased from Invitrogen.

[0056] 1. Construction of pcDNA expression vector

[0057] 1. Utilize the design software of Invitrogen Company, design pre-miRNA for hfgl2 prothrombinase gene, produce the single-stranded oligonucleotide sequence of hfgl2 prothrombinase miRNA:

[0058] 5'-TGCTGTTCTTTGAACACCTCCTCGATGTTTTGGCCACTGACTGACATCGAGGATGTTCAAAGAA-3'.

[0059] 2. Anneal the synthesized oligo single strands to form ds-oligo respectively: the reaction system is as follows:

[0060] Sense strand (200μM) 5μl

[0061] Antisense strand (200μM) 5μl

[0062] 10×oilgo annealing buffer 2μl

[0063] DNase / RNase-free pure water 8μl

[0064] Reaction conditions: water bath at 95°C for 4 minutes, place at room temperature for 10 minutes, centrifuge for 5 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of recombinant hfgl2 (Human Fibrinogen-like protein 2) micro RNA (ribonucleic acid) in liver cancer, in particular to application of micro RNA adenovirus expression particles for constructing hfgl2 prothrombinase genes related to liver cancer in the treatment of liver cancer as well as verification of pharmaceutical application of the micro RNA adenovirus expression particles. The adenovirus-mediated micro RNA interference technology, namely the recombinant hfgl2 micro RNA (hfgl2-miRNA adenovirus injection), is used for targeted treatment of liver cancer; a constructed highly-aggressive human liver cancer cell nude mouse subcutaneous transplantation tumor model is adopted; the recombinant hfgl2-miRNA adenovirus injection is injected into tumors throughmultiple points; and thus, the optimized therapeutic dose of the hfgl2-miRNA adenovirus injection is found by comparing the sizes of the tumors, implementing immunohistochemistry and using other methods. Besides, the result shows that a remarkable therapeutic effect is achieved and the silence of the hfgl2 has a potential clinical application value for the treatment of liver cancer.

Description

technical field [0001] The present invention relates to a gene therapy method for liver cancer, more particularly to the use of hfgl2 inhibitors to treat liver cancer, especially to the application of recombinant human hfgl2 microRNA in the preparation of drugs for treating liver cancer, that is, the construction of human fgl2 (Human Fibrinogen-like protein 2, hfgl2) MicroRNA adenovirus expressing particles of prothrombinase gene for treatment and verification of its pharmaceutical use in liver cancer. Background technique [0002] Malignant tumors are diseases that seriously endanger human life and health. There are about 1.6 million cancer patients in my country every year. Malignant tumors are surpassing cardiovascular disease as the number one cause of death. Cancer prevention and research is becoming a topic of increasing concern to scientists all over the world. [0003] Blood coagulation and angiogenesis are one of the important pathways of tumor occurrence and dev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K31/7105A61P35/00
Inventor 宁琴罗小平习东王鸣严伟明
Owner TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products